home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.440 -0.210 (-3.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day

February 01, 2023

From Candel Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 23, 2023

Via Benzinga

Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference

January 12, 2023

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Earnings Perspective: Return On Capital Employed ↗

December 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 16, 2022

Via Benzinga

Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

December 06, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

November 29, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

November 18, 2022

From Candel Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022 ↗

December 02, 2022

Via Benzinga

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

November 11, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 10, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

November 07, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation for November

November 01, 2022

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

October 26, 2022

From Candel Therapeutics

Via GlobeNewswire

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 21, 2022

Gainers

Via Benzinga

Looking Into Candel Therapeutics's Recent Short Interest ↗

October 21, 2022

Candel Therapeutics's (NASDAQ:CADL) short percent of float has risen 15.38% since its last report. The company recently reported that it has 57 thousand shares sold short, which is 0.3% of all regular...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 21, 2022

Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million.

Via Benzinga

Tesla, AT&T, AMD, Nvidia, Candel Therapuetics: What's Happening With These Top 5 Trending Stocks ↗

October 20, 2022

Major U.S. indices closed in the red on Thursday as investors continued to digest higher Treasury yields as well as key earnings. The yield in the benchmark U.S. 10-year Treasuries topped 4.239%, a...

Via Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Candel Secures European Medicines Agency Orphan Drug Status For Brain Tumour Candidate ↗

September 15, 2022

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on Candel Therapeutics’ (NASDAQ: CADL) application for orphan drug designation for...

Via Benzinga

Looking Into Candel Therapeutics's Return On Capital Employed ↗

August 26, 2022

Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 24, 2022

Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares moved upwards by 20.1% to $1.79 during Wednesday's after-market session. The market value of their outstanding shares is at $31.6 million.

Via Benzinga

38 Stocks Moving In Tuesday's Mid-Day Session ↗

April 19, 2022

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗

November 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...

Via Benzinga

54 Biggest Movers From Yesterday ↗

April 20, 2022

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com